Welcome to Needham

Needham & Company, LLC, a subsidiary of The Needham Group, Inc., is a nationally recognized investment banking and asset management firm focused solely on growth companies and their investors. Needham’s mission is to provide its clients with the long-term advice they need to achieve their business goals. The Firm's commitment to exceptional service is unusual in today’s business climate, and is born of a tradition which stresses integrity above all else. We strive to be front of mind, approachable and idea driven. Needham is actively engaged in the public and private capital markets, boasting a 29-year track record of executing complex transactions and the accompanying reputation for excellence in our markets.

Needham’s principal activities involve assisting our clients through a variety of advisory and transaction-related services, with a specific focus on:




  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • Vitesse Semiconductor Corporation (NASDAQ: VTSS) designs a diverse portfolio of high-performance semiconductor solutions for Carrier and Enterprise networks worldwide. Vitesse products enable the fastest-growing network infrastructure markets including Mobile Access/IP Edge, Cloud Computing and SMB/SME Enterprise Networking. Vitesse is a registered trademark of Vitesse Semiconductor Corporation in the United States and other jurisdictions. All other trademarks or registered trademarks mentioned herein are the property of their respective holders.

    NA

  • N/A

    N/A

  • Cempra, Inc. (Nasdaq: CEMP), is a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) is in a Phase 3 clinical trial for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. TAKSTA™ (CEM-102) is Cempra's second product candidate currently in a Phase 2 clinical trial for prosthetic joint infections. Both seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to use its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders.

    Cempra, Inc. raised $57.9 million in its follow-on offering at $7.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 1,021,429 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Cempra, Inc. for The principle purposes of this offering are to obtain additional capital to support our operations. We expect to use the net proceeds of this offering forpartial funding of the IV-to-oral Phase 3 clinical trial of solithromycin, working capital and general corporate and administrative purposes.

  • N/A

    N/A

  • EMC Corporation (NYSE: EMC) is a global leader in enabling businesses and service providers to transform their operations and deliver IT as a service. Fundamental to this transformation is cloud computing. Through innovative products and services, EMC accelerates the journey to cloud computing, helping IT departments to store, manage, protect and analyze their most valuable asset – information – in a more agile, trusted and cost-efficient way.

    EMC Corporation announced the pricing of a public offering of $5.5 billion aggregate principal amount of its senior notes. The offering consists of $2.5 billion of 1.875% notes due 2018, $2.0 billion of 2.650% notes due 2020 and $1.0 billion of 3.375% notes due 2023. EMC intends to use the net proceeds of the offering to satisfy cash payment obligations at the maturity, or upon the conversion, of EMC’s outstanding 1.75% convertible senior notes due 2013, which will mature on December 1, 2013, and for general corporate purposes, including stock repurchases, working capital needs and other business opportunities. Needham acted as a co-manager on the transaction.

  • Webcollage is based in Manhattan, is the world’s leading provider of rich product information to retailer web sites (and their mobile visitors). By perfecting a new form of channel-marketing, Webcollage helps manufacturers instantly publish content that increases sales, reduces return rates and improve conversions by up to 36%. Webcollage, used by over 1,000 manufacturers, provides tools to upload and update rich product content including video in real-time.

    Webcollage, the web’s leading SaaS platform for managing and publishing rich product information, completed its previously announced sale to Answers, the leading provider for trusted answers to the world’s questions. Webcollage is a perfect extension to Answers’ product suite for retailers and brands. Consumer manufacturers and retailers who trust Webcollage as a publishing platform can now benefit from Answers’ complementary products for product reviews, product Q&A, retailer reputation management, and branded consumer engagement. The terms of the transaction were not disclosed. Needham & Company acted as exclusive financial advisor to Webcollage.

  • Founded in 1998, Bluefly, Inc. is a leading online retailer of designer brands, fashion trends and superior value. Bluefly is headquartered in the heart of the Fashion District. In 2011, Bluefly expanded its portfolio, launching Belle & Clive, a members-only shopping destination that presents highly-curated selections of important brands via limited time sale events.

    Bluefly, Inc. (NASDAQ Capital Market: BFLY), a leading online retailer of fashion forward designer brands at superior value, announced that an affiliate of Clearlake Capital Group has purchased approximately 89% of the outstanding shares of Bluefly Inc. directly from the Company’s principal stockholders and also entered into an agreement with the Company to purchase additional shares from the Company that, in aggregate, represent in excess of 90% of the outstanding shares of Bluefly. Needham & Company acted as exclusive financial advisor to Bluefly, Inc.

  • ChannelAdvisor Corporation (NYSE: ECOM) is a leading provider of cloud-based e-commerce solutions that enable retailers and manufacturers to integrate, manage and optimize their merchandise sales across hundreds of online channels including Amazon, Google, eBay, Facebook and more. Through automation, analytics and optimization, ChannelAdvisor customers can leverage a single inventory feed to more efficiently list and advertise products online, and connect with shoppers to increase sales. Billions of dollars in merchandise value are driven through ChannelAdvisor’s platform every year, and thousands of customers use ChannelAdvisor’s solutions to help grow their businesses.

    ChannelAdvisor Corporation raised $92.6 million in its initial public offering at $14.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 862,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by ChannelAdvisor Corporation for working capital and other general corporate purposes, including expansion of our sales and marketing capabilities and international operations. In addition, we may use a portion of the proceeds from this offering for opportunistic acquisitions of complementary businesses, technologies or other assets.

  • VIVUS, Inc. (NASDAQ: VVUS) is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health.

    VIVUS, Inc. (NASDAQ: VVUS) issued $220.0 million aggregate principal amount of 4.50% convertible senior unsecured notes due May 1, 2020 in a private placement. VIVUS, Inc. anticipates using approximately $30 million of the net proceeds from the offering to pay the cost of a capped call transaction described below to be entered into with an affiliate of one of the initial purchasers, and the remainder of the net proceeds for continued commercialization of its products and development of its product candidates, and for general corporate purposes. Needham & Company acted as a co-manager on this transaction.

  • Cubic Corporation (NYSE: CUB) is the parent company of three major business segments: Defense Systems, Mission Support Services and Transportation Systems. Cubic Defense Systems is a leading provider of realistic combat training systems, cyber technologies, asset tracking solutions, and defense electronics. Mission Support Services is a leading provider of training, operations, maintenance, technical and other support services to the U.S. and allied nations. Cubic Transportation Systems is a leading provider of automated fare collection systems and services for public transit authorities.

    Cubic Corporation raised $106.0 million in its follow-on offering at $45.75 per share. Needham acted as a co-manager on the transaction. The selling shareholders will receive all of the proceeds from this offering, and Cubic Corporation will not receive any proceeds from the sale of shares in this offering.

  • ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders. ACADIA has a pipeline of product candidates led by pimavanserin, which is in Phase III development as a treatment for Parkinson's disease psychosis. ACADIA also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two advanced preclinical programs directed at Parkinson’s disease and other neurological disorders. All product candidates are small molecules that emanate from discoveries made at ACADIA.

    ACADIA Pharmaceuticals Inc. raised $115.0 million in its follow-on offering at $12.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,200,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by ACADIA Pharmaceuticals Inc. to fund ongoing and new clinical trials and development and commercialization efforts for pimavanserin and its other product candidates and for general corporate purposes, which may include research, development and commercialization expenses, capital expenditures, working capital, and general and administrative expenses.

  • 3D Systems (NYSE: DDD) is a leading global provider of 3D content-to-print solutions including 3D printers, print materials and on-demand custom parts services for professionals and consumers alike. The company also provides CAD modeling, reverse engineering and inspection software tools and consumer 3D printers, apps and services. Its expertly integrated solutions replace and complement traditional methods and reduce the time and cost of designing and manufacturing new products. 3D Systems products and services are used to rapidly design, communicate, prototype or produce real functional parts, empowering customers to create and make with confidence.

    3D Systems raised $345.0 million in its follow-on offering at $40.00 per share. Needham acted as the sole bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,125,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by 3D Systems for working capital and general corporate purposes, and to finance future acquisitions of other entities or their assets.

  • Isis Pharmaceuticals (NASDAQ: ISIS) is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH. Genzyme is also pursuing marketing approval of KYNAMRO in other markets. Isis' patents provide strong and extensive protection for its drugs and technology.

    Isis Pharmaceuticals raised $171.0 million in its follow-on offering at $19.00 per share. Needham acted as ta co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Isis Pharmaceuticals to increase its drug development activities, develop select drugs in its pipeline to later stages of development prior to partnering, and for general corporate and working capital purposes.

  • Perficient (NASDAQ: PRFT) is a leading information technology consulting firm serving Global 2000 and enterprise customers throughout North America. Perficient’s professionals serve clients from a network of offices across North America and three offshore locations, in Eastern Europe, India, and China. Perficient helps clients use Internet-based technologies to improve productivity and competitiveness, strengthen relationships with customers, suppliers and partners, and reduce information technology costs. Perficient, traded on the Nasdaq Global Select Market, is a member of the Russell 2000® index and the S&P SmallCap 600 index. Perficient is an award-winning “Premier Level” IBM business partner, a TeamTIBCO partner, a Microsoft National Systems Integrator and Gold Certified Partner, an EMC Select Services Team Partner, and an Oracle Platinum Partner.

    Perficient, Inc. (NASDAQ: PRFT), a leading information technology consulting firm serving Global 2000 and other large enterprise customers throughout North America, announced it has acquired northeastern U.S.-based TriTek Solutions, Inc. (“TriTek”), an IBM- focused enterprise content management and business process management consulting firm that generated $19 million in 2012 services revenue. The consideration paid in the transaction is approximately $18.5 million and includes $13.2 million in cash and approximately $5.3 million worth of Perficient common stock. Needham & Company provided a fairness opinion to the Board of Directors of Perficient as part of their advisory services.

  • Rally Software (NYSE: RALY) is a leading global provider of cloud-based solutions for managing Agile software development. The Rally Agile application lifecycle management (ALM) platform transforms the way organizations manage the software development lifecycle by closely aligning software development and strategic business objectives, facilitating collaboration, increasing transparency and automating manual processes. Companies use Rally to accelerate the pace of innovation, improve productivity and more effectively adapt to rapidly changing customer needs and competitive dynamics.

    Rally Software raised $96.6 million in its initial public offering at $14.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 900,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Rally Software for working capital and other general corporate purposes. In addition, they may use a portion of the net proceeds from this offering for acquisitions of, or investments in, complementary companies, products or technologies.

  • RDA Microelectronics (NASDAQ: RDA) is a fabless semiconductor company that designs, develops and markets wireless systems-on-chip and radio-frequency semiconductors for cellular, connectivity and broadcast applications. The Company's product portfolio currently includes baseband, radio-frequency front end modules, power amplifiers, transceivers, Bluetooth systems-on-chip, Wi-Fi, Bluetooth and FM combo chips, FM radio receivers, set-top box tuners, analog mobile television receivers, CMMB mobile television receivers, walkie-talkie transceivers and LNB satellite downconverters.

    RDA Microelectronics raised $77.2 million in its follow-on offering at $9.25 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by RDA Microelectronics to pay the expenses of the offering, which they estimate will be $1.1 million and which they are contractually obligated to pay under our second amended and restated shareholders agreement dated as of February 25, 2010. The company will not receive any of the proceeds from the sale of ADSs by the selling shareholders, including any ADSs subject to the underwriters' over-allotment option, although they will bear the costs, other than underwriting discounts and commissions, associated with those sales.

  • Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multi-drug resistant infections. Tetraphase's lead product candidate, eravacycline, is a fully synthetic tetracycline derivative being developed as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant infections, including multi-drug resistant Gram-negative infections.

    Tetraphase Pharmaceuticals, Inc. raised $75.0 million in its initial public offering at $7.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares will be used by Tetraphase Pharmaceuticals, Inc. to fund its planned pivotal Phase 3 program for eravacycline for the treatment of complicated intra-abdominal infections and complicated urinary tract infections and for working capital and other general corporate purposes.

  • Trulia, Inc. (NYSE: TRLA) is an online residential real estate site for home buyers, sellers, renters and real estate professionals. It lists properties for sale and rent as well as neighborhood information and community insights. The company is headquartered in downtown San Francisco and has offices in New York City and Denver, Colorado.

    Trulia, Inc. raised $212.5 million in its follow-on offering at $29.75 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 931,606 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Trulia, Inc. for working capital and other general corporate purposes, and expect to use some or all of such net proceeds to acquire or invest in complementary businesses, products, services, technologies, or other assets.

  • WageWorks, Inc. (NYSE: WAGE) is a leading provider of Consumer-Directed Benefits (CDBs) in the United States. WageWorks administers and operates a broad array of CDBs, including pretax spending accounts, such as health and dependent care Flexible Spending Accounts (FSAs), as well as Commuter Benefit Services, including transit and parking programs, Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs), and other employee benefits. WageWorks is headquartered in San Mateo, California, with offices in major locations throughout the United States.

    WageWorks, Inc. raised $155.4 million in its upsized follow-on offering at $24.00 per share. Needham acted as the sole bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 844,667 shares of common stock at the follow-on offering price to cover over-allotments. WageWorks, Inc. will not receive any proceeds from the sale of shares to be offered by the selling stockholders. The principal purposes of this offering are to facilitate an orderly distribution of shares for the selling stockholders, to increase the public float and to raise additional capital. The proceeds of the primary portion of the offering will be used to provide additional working capital for WageWorks, Inc. and general corporate purposes, including further expansion of sales and marketing efforts, continued investments in technology and development and for capital expenditures.

  • ANADIGICS, Inc. (NASDAQ: ANAD) designs and manufactures innovative radio frequency solutions for the growing cellular, WiFi, and infrastructure markets. Headquartered in Warren, NJ, ANADIGICS offers RF products with exceptional performance and integration to deliver a unique competitive advantage to OEMs and ODMs for mobile device, base station, CATV infrastructure, CATV subscriber, and industrial applications. The Company's award-winning solutions include power amplifiers, front-end ICs, front-end modules, line amplifiers, active splitters, tuners, and other RF components.

    ANADIGICS, Inc. raised $20.0 million in its follow-on offering at $2.00 per share. Needham acted as the sole bookrunner on the transaction. The net proceeds from the sale of the shares from the offering will be used by ANADIGICS, Inc. for working capital and general corporate purposes.

  • Hyperion Therapeutics, Inc. (NASDAQ: HPTX) is a commercial stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases and hepatology.

    Hyperion Therapeutics, Inc. raised $59.7 million in its upsized follow-on offering at $20.75 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Hyperion Therapeutics, Inc. to fund clinical development for Ravicti in HE; to fund Phase IV studies in UCD; and for working capital and general corporate purposes.

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • N/A

    N/A

  • Vitesse Semiconductor Corporation (NASDAQ: VTSS) designs a diverse portfolio of high-performance semiconductor solutions for Carrier and Enterprise networks worldwide. Vitesse products enable the fastest-growing network infrastructure markets including Mobile Access/IP Edge, Cloud Computing and SMB/SME Enterprise Networking. Vitesse is a registered trademark of Vitesse Semiconductor Corporation in the United States and other jurisdictions. All other trademarks or registered trademarks mentioned herein are the property of their respective holders.

    NA

  • N/A

    N/A

  • Cempra, Inc. (Nasdaq: CEMP), is a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) is in a Phase 3 clinical trial for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. TAKSTA™ (CEM-102) is Cempra's second product candidate currently in a Phase 2 clinical trial for prosthetic joint infections. Both seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to use its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders.

    Cempra, Inc. raised $57.9 million in its follow-on offering at $7.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 1,021,429 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Cempra, Inc. for The principle purposes of this offering are to obtain additional capital to support our operations. We expect to use the net proceeds of this offering forpartial funding of the IV-to-oral Phase 3 clinical trial of solithromycin, working capital and general corporate and administrative purposes.

  • N/A

    N/A

  • EMC Corporation (NYSE: EMC) is a global leader in enabling businesses and service providers to transform their operations and deliver IT as a service. Fundamental to this transformation is cloud computing. Through innovative products and services, EMC accelerates the journey to cloud computing, helping IT departments to store, manage, protect and analyze their most valuable asset – information – in a more agile, trusted and cost-efficient way.

    EMC Corporation announced the pricing of a public offering of $5.5 billion aggregate principal amount of its senior notes. The offering consists of $2.5 billion of 1.875% notes due 2018, $2.0 billion of 2.650% notes due 2020 and $1.0 billion of 3.375% notes due 2023. EMC intends to use the net proceeds of the offering to satisfy cash payment obligations at the maturity, or upon the conversion, of EMC’s outstanding 1.75% convertible senior notes due 2013, which will mature on December 1, 2013, and for general corporate purposes, including stock repurchases, working capital needs and other business opportunities. Needham acted as a co-manager on the transaction.

  • Webcollage is based in Manhattan, is the world’s leading provider of rich product information to retailer web sites (and their mobile visitors). By perfecting a new form of channel-marketing, Webcollage helps manufacturers instantly publish content that increases sales, reduces return rates and improve conversions by up to 36%. Webcollage, used by over 1,000 manufacturers, provides tools to upload and update rich product content including video in real-time.

    Webcollage, the web’s leading SaaS platform for managing and publishing rich product information, completed its previously announced sale to Answers, the leading provider for trusted answers to the world’s questions. Webcollage is a perfect extension to Answers’ product suite for retailers and brands. Consumer manufacturers and retailers who trust Webcollage as a publishing platform can now benefit from Answers’ complementary products for product reviews, product Q&A, retailer reputation management, and branded consumer engagement. The terms of the transaction were not disclosed. Needham & Company acted as exclusive financial advisor to Webcollage.

  • Founded in 1998, Bluefly, Inc. is a leading online retailer of designer brands, fashion trends and superior value. Bluefly is headquartered in the heart of the Fashion District. In 2011, Bluefly expanded its portfolio, launching Belle & Clive, a members-only shopping destination that presents highly-curated selections of important brands via limited time sale events.

    Bluefly, Inc. (NASDAQ Capital Market: BFLY), a leading online retailer of fashion forward designer brands at superior value, announced that an affiliate of Clearlake Capital Group has purchased approximately 89% of the outstanding shares of Bluefly Inc. directly from the Company’s principal stockholders and also entered into an agreement with the Company to purchase additional shares from the Company that, in aggregate, represent in excess of 90% of the outstanding shares of Bluefly. Needham & Company acted as exclusive financial advisor to Bluefly, Inc.

  • ChannelAdvisor Corporation (NYSE: ECOM) is a leading provider of cloud-based e-commerce solutions that enable retailers and manufacturers to integrate, manage and optimize their merchandise sales across hundreds of online channels including Amazon, Google, eBay, Facebook and more. Through automation, analytics and optimization, ChannelAdvisor customers can leverage a single inventory feed to more efficiently list and advertise products online, and connect with shoppers to increase sales. Billions of dollars in merchandise value are driven through ChannelAdvisor’s platform every year, and thousands of customers use ChannelAdvisor’s solutions to help grow their businesses.

    ChannelAdvisor Corporation raised $92.6 million in its initial public offering at $14.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 862,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by ChannelAdvisor Corporation for working capital and other general corporate purposes, including expansion of our sales and marketing capabilities and international operations. In addition, we may use a portion of the proceeds from this offering for opportunistic acquisitions of complementary businesses, technologies or other assets.

  • VIVUS, Inc. (NASDAQ: VVUS) is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health.

    VIVUS, Inc. (NASDAQ: VVUS) issued $220.0 million aggregate principal amount of 4.50% convertible senior unsecured notes due May 1, 2020 in a private placement. VIVUS, Inc. anticipates using approximately $30 million of the net proceeds from the offering to pay the cost of a capped call transaction described below to be entered into with an affiliate of one of the initial purchasers, and the remainder of the net proceeds for continued commercialization of its products and development of its product candidates, and for general corporate purposes. Needham & Company acted as a co-manager on this transaction.

  • Cubic Corporation (NYSE: CUB) is the parent company of three major business segments: Defense Systems, Mission Support Services and Transportation Systems. Cubic Defense Systems is a leading provider of realistic combat training systems, cyber technologies, asset tracking solutions, and defense electronics. Mission Support Services is a leading provider of training, operations, maintenance, technical and other support services to the U.S. and allied nations. Cubic Transportation Systems is a leading provider of automated fare collection systems and services for public transit authorities.

    Cubic Corporation raised $106.0 million in its follow-on offering at $45.75 per share. Needham acted as a co-manager on the transaction. The selling shareholders will receive all of the proceeds from this offering, and Cubic Corporation will not receive any proceeds from the sale of shares in this offering.

  • ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders. ACADIA has a pipeline of product candidates led by pimavanserin, which is in Phase III development as a treatment for Parkinson's disease psychosis. ACADIA also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two advanced preclinical programs directed at Parkinson’s disease and other neurological disorders. All product candidates are small molecules that emanate from discoveries made at ACADIA.

    ACADIA Pharmaceuticals Inc. raised $115.0 million in its follow-on offering at $12.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,200,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by ACADIA Pharmaceuticals Inc. to fund ongoing and new clinical trials and development and commercialization efforts for pimavanserin and its other product candidates and for general corporate purposes, which may include research, development and commercialization expenses, capital expenditures, working capital, and general and administrative expenses.

  • 3D Systems (NYSE: DDD) is a leading global provider of 3D content-to-print solutions including 3D printers, print materials and on-demand custom parts services for professionals and consumers alike. The company also provides CAD modeling, reverse engineering and inspection software tools and consumer 3D printers, apps and services. Its expertly integrated solutions replace and complement traditional methods and reduce the time and cost of designing and manufacturing new products. 3D Systems products and services are used to rapidly design, communicate, prototype or produce real functional parts, empowering customers to create and make with confidence.

    3D Systems raised $345.0 million in its follow-on offering at $40.00 per share. Needham acted as the sole bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,125,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by 3D Systems for working capital and general corporate purposes, and to finance future acquisitions of other entities or their assets.

  • Isis Pharmaceuticals (NASDAQ: ISIS) is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH. Genzyme is also pursuing marketing approval of KYNAMRO in other markets. Isis' patents provide strong and extensive protection for its drugs and technology.

    Isis Pharmaceuticals raised $171.0 million in its follow-on offering at $19.00 per share. Needham acted as ta co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Isis Pharmaceuticals to increase its drug development activities, develop select drugs in its pipeline to later stages of development prior to partnering, and for general corporate and working capital purposes.

  • Perficient (NASDAQ: PRFT) is a leading information technology consulting firm serving Global 2000 and enterprise customers throughout North America. Perficient’s professionals serve clients from a network of offices across North America and three offshore locations, in Eastern Europe, India, and China. Perficient helps clients use Internet-based technologies to improve productivity and competitiveness, strengthen relationships with customers, suppliers and partners, and reduce information technology costs. Perficient, traded on the Nasdaq Global Select Market, is a member of the Russell 2000® index and the S&P SmallCap 600 index. Perficient is an award-winning “Premier Level” IBM business partner, a TeamTIBCO partner, a Microsoft National Systems Integrator and Gold Certified Partner, an EMC Select Services Team Partner, and an Oracle Platinum Partner.

    Perficient, Inc. (NASDAQ: PRFT), a leading information technology consulting firm serving Global 2000 and other large enterprise customers throughout North America, announced it has acquired northeastern U.S.-based TriTek Solutions, Inc. (“TriTek”), an IBM- focused enterprise content management and business process management consulting firm that generated $19 million in 2012 services revenue. The consideration paid in the transaction is approximately $18.5 million and includes $13.2 million in cash and approximately $5.3 million worth of Perficient common stock. Needham & Company provided a fairness opinion to the Board of Directors of Perficient as part of their advisory services.

  • Rally Software (NYSE: RALY) is a leading global provider of cloud-based solutions for managing Agile software development. The Rally Agile application lifecycle management (ALM) platform transforms the way organizations manage the software development lifecycle by closely aligning software development and strategic business objectives, facilitating collaboration, increasing transparency and automating manual processes. Companies use Rally to accelerate the pace of innovation, improve productivity and more effectively adapt to rapidly changing customer needs and competitive dynamics.

    Rally Software raised $96.6 million in its initial public offering at $14.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 900,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Rally Software for working capital and other general corporate purposes. In addition, they may use a portion of the net proceeds from this offering for acquisitions of, or investments in, complementary companies, products or technologies.

  • RDA Microelectronics (NASDAQ: RDA) is a fabless semiconductor company that designs, develops and markets wireless systems-on-chip and radio-frequency semiconductors for cellular, connectivity and broadcast applications. The Company's product portfolio currently includes baseband, radio-frequency front end modules, power amplifiers, transceivers, Bluetooth systems-on-chip, Wi-Fi, Bluetooth and FM combo chips, FM radio receivers, set-top box tuners, analog mobile television receivers, CMMB mobile television receivers, walkie-talkie transceivers and LNB satellite downconverters.

    RDA Microelectronics raised $77.2 million in its follow-on offering at $9.25 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by RDA Microelectronics to pay the expenses of the offering, which they estimate will be $1.1 million and which they are contractually obligated to pay under our second amended and restated shareholders agreement dated as of February 25, 2010. The company will not receive any of the proceeds from the sale of ADSs by the selling shareholders, including any ADSs subject to the underwriters' over-allotment option, although they will bear the costs, other than underwriting discounts and commissions, associated with those sales.

  • Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multi-drug resistant infections. Tetraphase's lead product candidate, eravacycline, is a fully synthetic tetracycline derivative being developed as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant infections, including multi-drug resistant Gram-negative infections.

    Tetraphase Pharmaceuticals, Inc. raised $75.0 million in its initial public offering at $7.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares will be used by Tetraphase Pharmaceuticals, Inc. to fund its planned pivotal Phase 3 program for eravacycline for the treatment of complicated intra-abdominal infections and complicated urinary tract infections and for working capital and other general corporate purposes.

  • Trulia, Inc. (NYSE: TRLA) is an online residential real estate site for home buyers, sellers, renters and real estate professionals. It lists properties for sale and rent as well as neighborhood information and community insights. The company is headquartered in downtown San Francisco and has offices in New York City and Denver, Colorado.

    Trulia, Inc. raised $212.5 million in its follow-on offering at $29.75 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 931,606 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Trulia, Inc. for working capital and other general corporate purposes, and expect to use some or all of such net proceeds to acquire or invest in complementary businesses, products, services, technologies, or other assets.

  • WageWorks, Inc. (NYSE: WAGE) is a leading provider of Consumer-Directed Benefits (CDBs) in the United States. WageWorks administers and operates a broad array of CDBs, including pretax spending accounts, such as health and dependent care Flexible Spending Accounts (FSAs), as well as Commuter Benefit Services, including transit and parking programs, Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs), and other employee benefits. WageWorks is headquartered in San Mateo, California, with offices in major locations throughout the United States.

    WageWorks, Inc. raised $155.4 million in its upsized follow-on offering at $24.00 per share. Needham acted as the sole bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 844,667 shares of common stock at the follow-on offering price to cover over-allotments. WageWorks, Inc. will not receive any proceeds from the sale of shares to be offered by the selling stockholders. The principal purposes of this offering are to facilitate an orderly distribution of shares for the selling stockholders, to increase the public float and to raise additional capital. The proceeds of the primary portion of the offering will be used to provide additional working capital for WageWorks, Inc. and general corporate purposes, including further expansion of sales and marketing efforts, continued investments in technology and development and for capital expenditures.

  • ANADIGICS, Inc. (NASDAQ: ANAD) designs and manufactures innovative radio frequency solutions for the growing cellular, WiFi, and infrastructure markets. Headquartered in Warren, NJ, ANADIGICS offers RF products with exceptional performance and integration to deliver a unique competitive advantage to OEMs and ODMs for mobile device, base station, CATV infrastructure, CATV subscriber, and industrial applications. The Company's award-winning solutions include power amplifiers, front-end ICs, front-end modules, line amplifiers, active splitters, tuners, and other RF components.

    ANADIGICS, Inc. raised $20.0 million in its follow-on offering at $2.00 per share. Needham acted as the sole bookrunner on the transaction. The net proceeds from the sale of the shares from the offering will be used by ANADIGICS, Inc. for working capital and general corporate purposes.

  • Hyperion Therapeutics, Inc. (NASDAQ: HPTX) is a commercial stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases and hepatology.

    Hyperion Therapeutics, Inc. raised $59.7 million in its upsized follow-on offering at $20.75 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Hyperion Therapeutics, Inc. to fund clinical development for Ravicti in HE; to fund Phase IV studies in UCD; and for working capital and general corporate purposes.